Naida Omerović Ćorović

Dr. Naida Omerović Ćorović

Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina, Federation of, Bosnia and Herzegovina
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2019 in Health and Technology
Verified
Journal Article
Closed access
PDF file
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
Edina VranićEdina Vranić
Edina Vranić

26 December 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ognjenka RahicOgnjenka Rahic
Ognjenka Rahic
Amina Tucak SmajicAmina Tucak Smajic
Amina Tucak Smajic
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
Merima SirbubaloMerima Sirbubalo
Merima Sirbubalo
LHLamija Hindija
Lamija Hindija
Edina VranićEdina Vranić
Edina Vranić
Glaucoma is considered to be one of the biggest health problems in the world. It is the main cause of preventable blindness due to its asymptomatic nature in the early stages on the one hand and patients’ non-adherence on the other. There are several approaches in glaucoma treatment, whereby this has to be individually designed for each patient. The first-line treatment is medication therapy. However, taking into account numerous disadvantages of conventional ophthalmic dosage forms, intensive work has been carried out on the development of novel drug delivery systems for glaucoma. This review aims to provide an overview of formulation solutions and strategies in the development of in situ gel systems, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices. The results of studies confirming the effectiveness of the aforementioned drug delivery systems were also briefly presented.

25 June 2020 in Medical Archives
Verified
Journal Article
Open access
NZNermina Ziga-Smajic
Nermina Ziga-Smajic
SSSelma Skrbo
Selma Skrbo
SMSamija Muratovic
Samija Muratovic
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
DLDina Lagumdzija
Dina Lagumdzija
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
Hyperuricemia is an independent risk factor for the development of many diseases. The aim of this paper is to compare the effects of allopurinol and febuxostat on the values of triglycerides and uric acid in hyperuricemic patients. This was a pharmacological-clinical retrospective-prospective study. The research sample comprised 50 examinees of both genders and different ages who were undergoing allopurinol (100 mg/day) or febuxostat (80 mg/day) therapy. Statistical Product and Service Solutions (SPSS) Software and Microsoft Excel were used for statistical analysis. Examinees who were treated with allopurinol had a statistically significant decrease in uric acid concentrations (by 126.28 ± 20.36 μmol/l) at the end of the observation compared to the initial values (p = 0.006). Examinees who were treated with febuxostat had a statistically significant decrease in uric acid concentrations (by 252.80 ± 94.17 μmol/l) at the end of the observation compared to the initial values (p = 0.001). The initial value of triglycerides was 1.58 ± 0.64 mmol/l in allopurinol-treated examinees, and 1.60 ± 0.52 mmol/l in febuxostat-treated examinees. After three and six months of allopurinol use, there was a statistically significant increase in triglyceride values (p = 0.046 and p = 0.042, respectively). A statistically significant decrease in triglyceride values (by 0.16 ± 0.10 mmol/l) was noted after three months of febuxostat use (p = 0.012). The results of this research confirmed the previous findings and pointed out the positive pharmacological effects of allopurinol and febuxostat.

1 June 2021
Verified
Book Chapter
Closed access
PDF file
AHAzra Hamidović
Azra Hamidović
EHEna Hasković
Ena Hasković
SMSumeja Muhić
Sumeja Muhić
MPMatej Planinić
Matej Planinić
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
SŠSelma Škrbo
Selma Škrbo

23 January 2021 in Journal of Pharmaceutical Research International
Verified
Journal Article
Closed access
PDF file
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
ČKČaklovica Kenan
Čaklovica Kenan
LDLagumdžija Dina
Lagumdžija Dina
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
ŽNŽiga Smajić Nermina
Žiga Smajić Nermina
BFBečić Fahir
Bečić Fahir
The pursuance of novel antimicrobial and anti-inflammatory agents has been expanding due to a significant need for more efficient pharmacotherapy of various infections and chronic diseases. During the last decade, pharmacokinetics, pharmacodynamics and pharmacological properties of curcumin have been extensively studied. The aim of the present study was to evaluate the antibacterial activity of curcumin against both Gram-positive and Gram-negative bacteria as well as its antifungal activity by using in vitro agar well diffusion assay. Moreover, the anti-inflammatory activity of curcumin was determined with in vitro assay of inhibition of protein denaturation. Results demonstrated wide antimicrobial activity of curcumin upon all of the test bacteria and fungi. The strongest activity of curcumin was observed at a concentration of 0.50 mg/ml against S. aureus, L. monocytogenes, E. coli, P. aeruginosa and C. albicans, resulting in a maximum zone of inhibition of 14.7 mm, 14.3 mm, 13.7 mm, 10.7 mm and 10.7 mm, respectively. Findings suggested that the antimicrobial activity of curcuminis dependent upon the concentrations. Furthermore, results demonstrated high effectiveness of curcumin compared to standard acetylsalicylic acid in inhibiting heat-induced protein denaturation, which activity is also depended upon the concentrations. The present study emphasises the potential application of curcumin as a natural antimicrobial and anti-inflammatory agent. However, findings of this study are restricted to in vitro assays and consideration should be given to conducting a study involving wider dose range test substances as well as including further research on in vivo models.

1 June 2021
Verified
Book Chapter
Closed access
PDF file
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
KČKenan Čaklovica
Kenan Čaklovica
AŠAida Šapčanin
Aida Šapčanin
DLDina Lagumdžija
Dina Lagumdžija
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
FBFahir Bečić
Fahir Bečić